Zimbabwe has rejected a significant US health deal valued at 367 million US dollars (272 million pounds) spanning five years over the United States' request for sensitive biological samples.
This move became public following a internal memorandum from December was disclosed, revealing that President Emmerson Mnangagwa believed the agreement was "skewed".
An official representative later clarified that the United States was seeking health data for scientific study and commercial purposes but refused to guarantee the benefits from future treatments.
"We must now begin the difficult and regrettable process of winding down our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had provided over $1.9bn in health funding to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has appealed for more talks to secure a deal suitable to all parties so the nation's critical HIV treatment initiative can be sustained.
Wider Context
This rejection comes after a comparable case in Kenya, where a court blocked a related deal with the US following legal challenges were filed about the security of Kenyans' medical information.
Since returning to office recently, US President Donald Trump has drastically cut foreign aid and shut down the US Agency for International Development (USAID).
USAID had managed assistance for the US government, but Trump stated its spending was "inefficient" and his government was seeking government-to-government deals to boost transparency and accountability.
Based on statements, 16 nations in Africa have to date signed these new agreements, representing over $18.3bn in committed funds.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this cooperation might have yielded extraordinary benefits for the people of Zimbabwe, especially the 1.2 million currently receiving HIV treatment through US-supported programmes," the Ambassador added.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to provide its biological resources and data indefinitely, with no corresponding assurance of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," he stated.
"In essence, our nation would supply the raw materials for medical research with no certainty that the end products would be accessible to our citizens should a future pandemic arise."
Sovereignty and Global Health
He also said that the American exit from the global health body and its pursuit of bilateral deals were disrupting systems already set up through the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing framework created to deal with future global health emergencies.
"This framework is intended to guarantee that when a country provides its samples, the benefits – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the resources to create them."
Zimbabwe's reservations regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We are open to ongoing discussions with our US partners on how future co-operation might be structured in a manner that respects the independence and interests of both nations."
Medical Community Response
Medical experts stated it recognised the official position, but urged that talks should continue since much of the country's HIV programmes depended on external financing.
"If technical issues arise, such as those involving information security or implementation frameworks, these can often be addressed via detailed discussion and negotiated safeguards," the group commented.
The situation emphasises the continuing tensions between accepting crucial international aid and safeguarding national sovereignty in an ever more data-driven world.